Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI23P819K)
  Drug Name Bromocriptine Drug Info Amyl Nitrite Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiparkinson Agents Antidotes
  Structure

 Mechanism of Bromocriptine-Amyl Nitrite Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Bromocriptine Amyl Nitrite
      Mechanism 1 Antihypertensive agent Hypotensive effects
Guanylate cyclase  Agonist
      Key Mechanism Factor 1
Factor Name Guanylate cyclase soluble Structure Sequence
Protein Family Adenylyl cyclase class-4/guanylyl cyclase family
Protein Function
There are two types of guanylate cyclases: soluble forms and membrane-associated receptor forms. Activated by nitric oxide in the presence of magnesium or manganese ions.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Bromocriptine and Amyl Nitrite 
      Mechanism 2 Hypotensive effects Hypotensive effects
Guanylate cyclase  Agonist
      Key Mechanism Factor 2
Factor Name Guanylate cyclase soluble Structure Sequence
Protein Family Adenylyl cyclase class-4/guanylyl cyclase family
Protein Function
There are two types of guanylate cyclases: soluble forms and membrane-associated receptor forms. Activated by nitric oxide in the presence of magnesium or manganese ions.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Bromocriptine and Amyl Nitrite 

Recommended Action
      Management This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.

References
1 Product Information. D.H.E. 45 (dihydroergotamine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
2 Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51
3 Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9